Table 2. Screening program indicators among women aged 25–64, by urban residential zone of Manaus, Brazil. 2019.
| Zone | Women population (age 25 to 64) | Cytology tests (only satisfatory samples) | Unsatisfatory cytology samples (%) | Annual coverage of target population (%) | Percent of cytology tests HSIL+ (%) | Cervical cancers cases at reference cancer hospital (June-Dec 2019) | Annual number of cancers per 100,000 women age 25–64* (Confidence Interval) |
|---|---|---|---|---|---|---|---|
| South | 133,950 | 14,548 | 1.26 | 32.6 | 1.8 | 38 | 48.5 (37.4–61.8) |
| West | 128,532 | 14,272 | 1.38 | 33.3 | 2.0 | 32 | 42.7 (32.2–55.6) |
| North | 153,706 | 21,967 | 1.22 | 42.9 | 2.1 | 35 | 39.0 (29.7–50.2) |
| East | 120,818 | 19,779 | 1.43 | 49.1 | 2.5 | 27 | 38.1 (27.8–50.0) |
| TOTAL | 537,006 | 70,566 | 1.33 | 39.4 | 2.1 | 132 |
p-value <.001 <.001.
HSIL+: High-grade intraepithelial lesion or worse (includes atypical squamous cells high-grade (ASC-H, atypical glandular cells of undetermined significance (AGUS) and cancer). Screening coverage is number of screening cytologies among target population (1/3 of women age 25–64 in Manaus).
*Extrapolated from number of cases during 7-month period from June–December 2019. Cervical cancer includes only cases treated at FCECON. Chi-square p-value for trend.